209
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Cutaneous Methotrexate-Related Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review

, ORCID Icon, ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 2229-2235 | Received 02 May 2023, Accepted 03 Aug 2023, Published online: 15 Aug 2023

References

  • Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–516. doi:10.1016/j.ejmech.2018.09.027
  • Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172(6):369–380. doi:10.7326/M19-3369
  • Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–331.
  • Kojima M, Itoh H, Hirabayashi K, et al. Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006;202(9):679–685. doi:10.1016/j.prp.2006.05.007
  • Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14(6):1943–1949. doi:10.1200/JCO.1996.14.6.1943
  • Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. J Cutan Pathol. 2011;38(3):295–297. doi:10.1111/j.1600-0560.2009.01459.x
  • Rausch T, Cairoli A, Benhattar J, Spring P, Hohl D, de Leval L. EBV+ cutaneous B-cell lymphoproliferation of the leg in an elderly patient with mycosis fungoides and methotrexate treatment. APMIS. 2013;121(1):79–84. doi:10.1111/j.1600-0463.2012.02939.x
  • Ingen-Housz-Oro S, Ortonne N, Cordel N, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with Sezary syndrome treated by methotrexate. Br J Dermatol. 2016;175(2):430–433. doi:10.1111/bjd.14602
  • Maderal AD, Malone JC, Callen JP. Methotrexate-Associated B-Cell Lymphoproliferative Disease in a Patient With Cutaneous T-Cell Lymphoma. JAMA Dermatol. 2018;154(4):490–492. doi:10.1001/jamadermatol.2017.6062
  • Delaleu J, Maubec E, Rodrigues F, et al. Methotrexate-induced Primary Cutaneous Diffuse Large B-cell Lymphoma in Patients with Erythrodermic Cutaneous T-cell Lymphoma. Acta Derm Venereol. 2020;100(15):adv00226. doi:10.2340/00015555-3554
  • Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108(6):1271–1280. doi:10.1111/cas.13249
  • Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–28. doi:10.1111/ejh.12116
  • Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;59(5):1143–1152. doi:10.1080/10428194.2017.1369073
  • Kaji D, Kusakabe M, Sakata-Yanagimoto M, et al. Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases. Br J Haematol. 2021;195(4):585–594. doi:10.1111/bjh.17824
  • Ohkura Y, Shindoh J, Haruta S, et al. Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy. Medicine. 2015;94(31):e1270. doi:10.1097/MD.0000000000001270
  • Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
  • Shimizu S, Inokuma D, Murata J, et al. Cutaneous manifestations of methotrexate-associated lymphoproliferative disorders: report of two cases and a review of the literature. Acta Derm Venereol. 2015;95(3):366–367. doi:10.2340/00015555-1951
  • Dobos G, Pohrt A, Ram-Wolff C, et al. Epidemiology of Cutaneous T-Cell Lymphomas: a Systematic Review and Meta-Analysis of 16,953 Patients. Cancers. 2020;12(10):2921. doi:10.3390/cancers12102921
  • Barzilai A, Trau H, David M, et al. Mycosis fungoides associated with B-cell malignancies. Br J Dermatol. 2006;155(2):379–386. doi:10.1111/j.1365-2133.2006.07346.x
  • Satou A, Banno S, Kohno K, et al. Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features. Pathology. 2021;53(5):595–601. doi:10.1016/j.pathol.2020.10.019